Near VA improves with topical presbyopia treatment

The PRX ophthalmic solution from Presbyopia Therapies LLC demonstrated a statistically significant three line or greater improvement in monocular distance corrected near visual acuity in a phase 2b trial, meeting primary efficacy and safety endpoints, the company announced in a press release.

Conducted by Ora Inc., the randomized, double-masked, placebo-controlled study enrolled 58 patients between the ages of 48 and 64 years and evaluated two unique miotic-based PRX test candidates, the release said.

One hour after instillation, 47.2% of study eyes gained at least three lines (P < .001), while 91.7% gained at least two lines of near visual acuity. At least a two-line improvement was maintained for up to 7 hours in about half of study eyes, according to the release.

“This unique drug was well-tolerated, with no significant loss in monocular best corrected distance visual acuity in study eyes, and no serious adverse events,” the release stated.

 

The PRX ophthalmic solution from Presbyopia Therapies LLC demonstrated a statistically significant three line or greater improvement in monocular distance corrected near visual acuity in a phase 2b trial, meeting primary efficacy and safety endpoints, the company announced in a press release.

Conducted by Ora Inc., the randomized, double-masked, placebo-controlled study enrolled 58 patients between the ages of 48 and 64 years and evaluated two unique miotic-based PRX test candidates, the release said.

One hour after instillation, 47.2% of study eyes gained at least three lines (P < .001), while 91.7% gained at least two lines of near visual acuity. At least a two-line improvement was maintained for up to 7 hours in about half of study eyes, according to the release.

“This unique drug was well-tolerated, with no significant loss in monocular best corrected distance visual acuity in study eyes, and no serious adverse events,” the release stated.